Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Renal Cell Carcinoma
Interventions
DRUG

Erlotinib hydrochloride

Patients will receive single-agent Tarceva, 150 mg/day

DRUG

Sirolimus

Patients will receive a loading dose of 6 mg of Rapamune seven days after beginning treatment with Tarceva™ followed by a dose of 2mg/day.

Trial Locations (1)

80010

University of Colorado Hospital, Aurora

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of Colorado, Denver

OTHER